HRD

News alerts, weekly reports and conference planners

Related biomarkers:

HRD	Fallopian Tube Cancer	HRD	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Peritoneal Cancer	HRD	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Peritoneal Cancer	HRD	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Fallopian Tube Cancer	HRD	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B	ABT-888 Sensitive: B - Late Trials ABT-888 Sensitive : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	atezolizumab Resistant: B - Late Trials atezolizumab Resistant : B	atezolizumab Resistant: B - Late Trials atezolizumab Resistant : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	Sensitive: B - Late Trials Sensitive : B	Sensitive: B - Late Trials Sensitive : B
HRD	Breast Cancer	HRD	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
HRD	Prostate Cancer	HRD	Prostate Cancer	niraparib Sensitive: B - Late Trials niraparib Sensitive : B	niraparib Sensitive: B - Late Trials niraparib Sensitive : B
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
HRD	HER2 Negative Breast Cancer	HRD	HER2 Negative Breast Cancer	olaparib Resistant: C1 - Off-label olaparib Resistant : C1	olaparib Resistant: C1 - Off-label olaparib Resistant : C1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	tislelizumab-jsgr Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr Sensitive : C2	tislelizumab-jsgr Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr Sensitive : C2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria bevacizumab + niraparib Sensitive : C2	bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria bevacizumab + niraparib Sensitive : C2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2
HRD	Breast Cancer	HRD	Breast Cancer	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria olaparib + durvalumab Sensitive : C2	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria olaparib + durvalumab Sensitive : C2
HRD	Non Small Cell Lung Cancer	HRD	Non Small Cell Lung Cancer	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3
HRD	Gastric Cancer	HRD	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3
HRD	Prostate Cancer	HRD	Prostate Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
HRD	Prostate Cancer	HRD	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
HRD	Ovarian Cancer	HRD	Ovarian Cancer	ABT-767 Sensitive: C3 – Early Trials ABT-767 Sensitive : C3	ABT-767 Sensitive: C3 – Early Trials ABT-767 Sensitive : C3
HRD	Ovarian Cancer	HRD	Ovarian Cancer	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3

HRD

Associations